GB201905810D0 - Method of treatment - Google Patents
Method of treatmentInfo
- Publication number
- GB201905810D0 GB201905810D0 GBGB1905810.6A GB201905810A GB201905810D0 GB 201905810 D0 GB201905810 D0 GB 201905810D0 GB 201905810 A GB201905810 A GB 201905810A GB 201905810 D0 GB201905810 D0 GB 201905810D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1905810.6A GB201905810D0 (en) | 2019-04-25 | 2019-04-25 | Method of treatment |
GBGB2000955.1A GB202000955D0 (en) | 2019-04-25 | 2020-01-22 | Method of treatment |
AU2020263709A AU2020263709A1 (en) | 2019-04-25 | 2020-03-04 | Method of treatment |
US17/604,509 US20220211810A1 (en) | 2019-04-25 | 2020-03-04 | Method of Treatment |
JP2021563064A JP2022530068A (en) | 2019-04-25 | 2020-03-04 | Treatment |
CN202080046367.0A CN114072206A (en) | 2019-04-25 | 2020-03-04 | Method of treatment |
PCT/EP2020/055741 WO2020216513A1 (en) | 2019-04-25 | 2020-03-04 | Method of treatment |
CA3137240A CA3137240A1 (en) | 2019-04-25 | 2020-03-04 | Method of treatment |
KR1020217037686A KR20220018963A (en) | 2019-04-25 | 2020-03-04 | treatment method |
EP20710849.9A EP3958974A1 (en) | 2019-04-25 | 2020-03-04 | Method of treatment |
IL287250A IL287250A (en) | 2019-04-25 | 2021-10-13 | Method of treatment |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1905810.6A GB201905810D0 (en) | 2019-04-25 | 2019-04-25 | Method of treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201905810D0 true GB201905810D0 (en) | 2019-06-05 |
Family
ID=66810336
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB1905810.6A Ceased GB201905810D0 (en) | 2019-04-25 | 2019-04-25 | Method of treatment |
GBGB2000955.1A Ceased GB202000955D0 (en) | 2019-04-25 | 2020-01-22 | Method of treatment |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB2000955.1A Ceased GB202000955D0 (en) | 2019-04-25 | 2020-01-22 | Method of treatment |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220211810A1 (en) |
EP (1) | EP3958974A1 (en) |
JP (1) | JP2022530068A (en) |
KR (1) | KR20220018963A (en) |
CN (1) | CN114072206A (en) |
AU (1) | AU2020263709A1 (en) |
CA (1) | CA3137240A1 (en) |
GB (2) | GB201905810D0 (en) |
IL (1) | IL287250A (en) |
WO (1) | WO2020216513A1 (en) |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4772667B2 (en) | 2003-06-02 | 2011-09-14 | エヴォルーテック・リミテッド | Complement inhibitor |
GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
WO2008029169A2 (en) | 2006-09-08 | 2008-03-13 | Varleigh Limited | Method of treating respiratory disorders |
DK2369005T3 (en) | 2007-06-21 | 2013-06-24 | Univ Muenchen Tech | Biologically active proteins with increased stability in vivo and / or in vitro |
GB0802116D0 (en) * | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
GB0906779D0 (en) * | 2009-04-20 | 2009-06-03 | Natural Environment Res Council | Composition |
PL2521562T3 (en) | 2010-01-08 | 2020-04-30 | Volution Immuno Pharmaceuticals Sa | Ev576 for use in the treatment of viral infections of the respiratory tract |
WO2016198133A1 (en) | 2015-06-08 | 2016-12-15 | Volution Immuno Pharmaceuticals Sa | Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease |
KR20190036520A (en) * | 2016-06-27 | 2019-04-04 | 아칠리온 파르마세우티칼스 인코포레이티드 | Quinazoline and indole compounds for the treatment of medical disorders |
AU2018226872A1 (en) * | 2017-03-03 | 2019-09-05 | Macregen, Inc. | Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents |
CN110831617A (en) | 2017-04-21 | 2020-02-21 | 沃卢申伊缪诺制药公司 | Coversin for the treatment of cicatricial ocular inflammatory disorders |
GB201706406D0 (en) | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
-
2019
- 2019-04-25 GB GBGB1905810.6A patent/GB201905810D0/en not_active Ceased
-
2020
- 2020-01-22 GB GBGB2000955.1A patent/GB202000955D0/en not_active Ceased
- 2020-03-04 EP EP20710849.9A patent/EP3958974A1/en active Pending
- 2020-03-04 AU AU2020263709A patent/AU2020263709A1/en active Pending
- 2020-03-04 US US17/604,509 patent/US20220211810A1/en active Pending
- 2020-03-04 CA CA3137240A patent/CA3137240A1/en active Pending
- 2020-03-04 JP JP2021563064A patent/JP2022530068A/en active Pending
- 2020-03-04 CN CN202080046367.0A patent/CN114072206A/en active Pending
- 2020-03-04 WO PCT/EP2020/055741 patent/WO2020216513A1/en unknown
- 2020-03-04 KR KR1020217037686A patent/KR20220018963A/en unknown
-
2021
- 2021-10-13 IL IL287250A patent/IL287250A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020263709A1 (en) | 2021-12-23 |
KR20220018963A (en) | 2022-02-15 |
IL287250A (en) | 2021-12-01 |
US20220211810A1 (en) | 2022-07-07 |
WO2020216513A1 (en) | 2020-10-29 |
GB202000955D0 (en) | 2020-03-04 |
EP3958974A1 (en) | 2022-03-02 |
CA3137240A1 (en) | 2020-10-29 |
JP2022530068A (en) | 2022-06-27 |
CN114072206A (en) | 2022-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB201804514D0 (en) | Treatment of pyroptosis | |
SG11202104222TA (en) | Method of treatment of biological surfaces | |
EP3684342A4 (en) | Method of treatment | |
GB201706406D0 (en) | Method of treatment | |
GB201815588D0 (en) | Method of treatment | |
GB201804515D0 (en) | Treatment of necroptosis | |
IL287210A (en) | Method of treating tumours | |
GB202005231D0 (en) | Method of mimimising patient risk | |
SG11202105877YA (en) | Method of treatment | |
GB201907305D0 (en) | Treatment of conditions | |
IL268111A (en) | Methods of treating pain | |
PL3431656T3 (en) | Method for the treatment of ballast | |
IL287250A (en) | Method of treatment | |
IL290983A (en) | Methods of treatment | |
GB201918853D0 (en) | Methods of treatment | |
GB201820236D0 (en) | Method of treatment | |
GB201820157D0 (en) | Method of treatment | |
GB201900942D0 (en) | Methods of treatment | |
GB201806569D0 (en) | Method of treatment | |
GB201804021D0 (en) | Method of treatment | |
AU2019903303A0 (en) | Method of Treatment | |
GB201917253D0 (en) | Treatment of conditions | |
AU2018904581A0 (en) | Method of treatment | |
AU2019901742A0 (en) | Method of treatment | |
AU2019901280A0 (en) | Method of Treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |